Aug 11, 2022 8:00am EDT Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
Aug 02, 2022 7:00am EDT Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign
Jun 23, 2022 8:00am EDT Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond
Mar 30, 2022 4:15pm EDT Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022
Feb 24, 2022 8:00am EST Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Feb 09, 2022 8:00am EST Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger
